Withania somnifera (Ashwagandha) in Breast Cancer: An in Vitro Review of Multi-Target Antitumor Mechanisms

Abstract

Abstract

Background:
Withania somnifera (Ashwagandha) has gained significant attention in oncology due to its diverse bioactive components and multifaceted pharmacological properties. Breast cancer remains a major cause of global morbidity and mortality, characterized by molecular heterogeneity and therapeutic resistance. This review summarizes in vitro evidence of its anticancer effects in breast cancer, with a focus on mechanistic pathways and tumour subtype responses.

Materials and Methods:
Peer-reviewed in vitro studies demonstrating the anticancer effects of Withania somnifera in breast cancer cell models were analyzed and summarized. Evaluated outcomes included cytotoxicity, apoptosis induction, cell cycle regulation, oxidative stress modulation, and inhibition of cell proliferation, angiogenesis, and metastatic progression. A comprehensive overview was developed by integrating mechanistic insights into relevant molecular signaling pathways.

Conclusion:
In vitro evidence supports Withania somnifera as a promising multi-target anticancer candidate with potential relevance in integrative breast cancer management. However, clinical translation requires standardized formulations, pharmacokinetic evaluation, and in vivo validation to establish safety and efficacy.

DOI: https://doi.org/10.24321/2394.6547.202601

How to Cite this Article:

Sharma A, Rai S, Tripathi R, More A. Withania somnifera (Ashwagandha) in Breast Cancer: An In Vitro Review of Multi-Target Antitumor Mechanisms. Journal of Advanced Research in Ayurvedic, Yoga, Unani, Siddha and Homeopathy. 2026;13(1&2):7–18.